Jennifer Eng-Wong MD
Assistant Professor, Medicine, Georgetown University School of Medicine
Join to View Full Profile
3800 Reservoir Rd NwLombardi Cancer CenterWashington, DC 20007
Phone+1 202-444-4948
Dr. Eng-Wong is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
University of California Davis HealthResidency, Internal Medicine, 1996 - 1999
Stony Brook University Health Sciences Center School of MedicineClass of 1996
Certifications & Licensure
DC State Medical License 2000 - 2013
MD State Medical License 2010 - 2012
Clinical Trials
- Raloxifene in Preventing Breast Cancer in Premenopausal Women Start of enrollment: 1998 Dec 01
- A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Publications & Presentations
PubMed
- ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ERbreast cancer.Jackson Liang, Xiaosai Yao, Patrick Aouad, Bu-Er Wang, Lisa Crocker
Nature Cancer. 2025-02-01 - 3 citationsPhase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Meta...Komal L Jhaveri, Meritxell Bellet, Nicholas C Turner, Sherene Loi, Aditya Bardia
Clinical Cancer Research. 2024-02-16 - Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer.Vikram Malhi, Priya Agarwal, Mary R Gates, Lichuan Liu, Jianshuang Wang
Cancer Research Communications. 2023-12-15
Authored Content
- Long-Term Efficacy Analysis of the Randomised, Phase II TRYPHAENA Cardiac Safety Study: Evaluating Pertuzumab and Trastuzumab plus Standard Neoadjuvant Anthracycline-Containing and Anthracycline-Free Chemotherapy Regimens in Patients with HER2-Positive Early Breast CancerJanuary 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
